12:00 AM
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dextofisopam: Phase IIb amended

Pharmos amended an ongoing, double-blind, U.S. Phase IIb trial of dextofisopam and will decrease enrollment from a planned 480 to 300 female patients. The company said it made the changes after concluding a reduction in the...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >